Mitesh Shah
India
Research Article
A Prospective, Multicentre, Single Arm Clinical Study to Evaluate the Effect of Saroglitazar on Non High-Density Lipoprotein Cholesterol in Patients with Diabetic Dyslipidemia Inadequately Controlled with Diet, Exercise, and Statin-The GLIDDER Study
Author(s): Upendra Kaul, Priyadarshini Arambam, Ranjan Kachru, Vineet Bhatia, Yumnam Diana, Nungshijungla, Mitesh Shah, Krupi Parmar, Ashok Jaiswal and Peeyush JainUpendra Kaul, Priyadarshini Arambam, Ranjan Kachru, Vineet Bhatia, Yumnam Diana, Nungshijungla, Mitesh Shah, Krupi Parmar, Ashok Jaiswal and Peeyush Jain
Objective: Diabetic dyslipidemia is highly atherogenic as it is associated with high triglyceride (TG), high small dense low-density lipoprotein (sd-LDL) particles and low high-density lipoprotein cholesterol (HDL-C). Saroglitazar, a dual peroxisome proliferator activated receptor agonist (predominant PPAR-α agonist and modest PPAR-γ agonist), is approved in India for the management of diabetic dyslipidemia. The GLIDDER study was done to evaluate the effects of Saroglitazar 4 mg on non HDL-C as the primary endpoint and sd-LDL particles as a secondary endpoint in diabetic patients with dyslipidemia.
Methods: This study was a 24 weeks, prospective, multicentre, single arm study conducted in 104 patients with diabetic dyslipidemia (TG ≥ 200 mg/dL) inadequately controlled w.. View More»
